OSE — Ose Immunotherapeutics SA Share News
0.000.00%
Last trade - 00:00- €44.94m
- €57.66m
- €2.69m
Brief: Ose Immunotherapeutics H1 Cons. Net Loss At EUR 11.9 Mln
Brief: OSE Immunotherapeutics Announces New Public Grant In Field Of RNA Therapeutics
Brief: Ose Immunotherapeutics Announces Article Publication On OSE-230 Therapy
Brief: OSE Immunotherapeutics/Lusvertikimab: Positive Review from DSMB On Phase 2 Clinical Trial in Ulcerative Colitis
Brief: Ose Immunotherapeutics Announces New Us Patent Granted For Tedopi®
French and Benelux stocks-Factors to watch
Brief: OSE Immunotherapeutics Receives €1.5 Mln In Funding From Bpifrance
Brief: Ose Immunotherapeutics Presents Clinical Abstracts On Tedopi® At ASCO 2023 Annual Meeting
Brief: Ose Immunotherapeutics To Continue Clinical Development In Ulcerative Colitis With Full Rights To Lusvertikimab
Brief: OSE Immunotherapeutics To Continue Clinical Development In Ulcerative Colitis, Transfers Full Rights To Lusvertikimab
Brief: Ose Immunotherapeutics Reports Full Year Financial Results
Brief: Ose Immunotherapeutics Provides Preclinical Updates On Clec-1 Myeloid Immune Checkpoint
Brief: OSE Immunotherapeutics Presents Clinical And Preclinical Data From Its Immuno-Oncology Portfolio
Brief: Ose Immunotherapeutics Receives New Approval For Early Access Program For Tedopi In Spain
Brief: Ose Immunotherapeutics Updates On Anti-IL-7 Receptor Antagonist OSE-127/S95011
Brief: Ose Immunotherapeutics Receives EUR 10 Mln Payment Corresponding To Second Tranche Of EIB Financing
Brief: OSE, Servier Complete Patient Enrollment In Sjogren's Syndrome Study
Brief: Ose Immunotherapeutics Updates On Cancer Vaccine Tedopi
Brief: Ose Immunotherapeutics Appoints Nicolas Poirier As CEO